Randomized, Single-Blind, Placebo-Controlled Multicenter Trial to Compare the Efficacy and Safety of Metronidazole and Satranidazole in Patients With Amebic Liver Abscess
- First Online:
- 130 Downloads
The aims of our randomized, single-blind trial involving 49 patients were to study the efficacy, side effects, and tolerance of metronidazole and satranidazole in patients of amebic liver abscess. Twenty-five patients received metronidazole (800 mg TID) and 24 received satranidazole (300 mg TID with placebo at mealtime). Patients recorded side effects and tolerability through a performa. The time taken for resolution of fever and pain and the fall in abscess size was not significant. However, tolerance of satranidazole as reported by the patients was significantly better than metronidazole (P < .005). The incidence of adverse effects was significantly lower in the group given satranidazole (P < .005). The incidence of nausea and metallic taste was significantly lower in the patients given satranidazole (P < .005). Thus, despite having a similar efficacy, satranidazole showed a far lower incidence of side effects and had a significantly better tolerance than Metronidazole.
KeywordsHepatic amebiasis Metronidazole Satranidazole Randomized control trial
- 1.Nair MD, Nagarajan K (1983) Nitroimidazoles as chemotherapeutic agents. In: Jucker E (ed) Progress in drug research, Vol 27. Birkhauser Verlag, Basel, pp 163–252Google Scholar
- 3.Ray DK, Shrivastava VB, Tendulkar JS, Dutta AK, Bhopale KK, Chatterjee DK, Nagarajan K (1983) Comparative studies on the amebicidal activity of known 5-nitroimidazole derivatives and CG-10213-Go in golden hamsters, Mesocricetus auratus, infected in the liver or caecum or both with trophozoites of Entamoeba histolytica. Ann Trop Med Parasitol 77:287–291PubMedGoogle Scholar
- 7.Bhatia S, Karnad DR, Loak J (1998) Randomized double-blind trial of Metronidazole versus secnidazole in amebic liver abscess. Ind J Gastroenterol 17:53–54Google Scholar